Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
126. |
ECCT/19/05/03 | SEARCH Supportive Care and Antibiotics for Severe Pneumonia among Hospitalised Children |
Principal Investigator(s) 1. Ambrose Agweyu Site(s) in Kenya 1. Mama Lucy Kibaki Hospital (Nairobi City county) 2. Kiambu County Referral Hospital (Kiambu county) 3. Machakos County Referral Hospital (Machakos county) 4. Embu County Referral Hospital (Embu county) 5. Naivasha County Hospital (Nakuru county) 6. Bungoma County Referral Hospital (Bung\'oma county) 7. Busia County Referral Hospital (Busia county) 8. Kitale County Referral Hospital (Trans Nzoia county) 9. Kisumu East Hospital (Kisumu county) 10. Kakamega County Referral Hospital, Kenya (Kakamega county) |
View |
127. |
ECCT/19/04/05 | PHOENIx MDR-TB A5300B/I2003B/PHOENIx "Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients" |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
View |
128. |
ECCT/19/04/03 | Phase III pediatric study with the L-PZQ ODTs An Open-label, Phase 3 efficacy and safety study of L-praziquantel orodispersible tablets (L-PZQ ODT) in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial PZQ (Biltricide®) |
Principal Investigator(s) 1. Maurice Reuben Odiere Site(s) in Kenya KEMRI-Centre for Global Health Research (CGHR) |
View |
129. |
ECCT/19/04/02 | NADIA \"Nucleosides And Darunavir/Dolutegravir In Africa\" A randomised controlled trial of darunavir versus dolutegravir and tenofovir versus zidovudine in second-line antiretroviral therapy regimens for the public health approach in sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya Moi University Clinical Research Centre |
View |
130. |
ECCT/19/03/02 | PREVENT TD A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD) |
Principal Investigator(s) 1. Flynn Alexander Site(s) in Kenya Nyati Barracks, British Army Training Unit, Kenya |
View |